Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.

Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.

Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.

Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.

Abstract: The present invention relates to a method for producing a porous material comprising the steps of; (a) providing a C/W emulsion comprising an aqueous phase, a matrix building material, a surfactant and liquid CO2 phase; (b) at least partially freezing the aqueous phase; (c) gasifying CO2 from the liquid CO2 phase to form an intermediate porous material; (d) venting gasified CO2 from the intermediate porous material; and (e) freeze drying the intermediate porous material at least substantially to remove the aqueous phase and form the porous material. The present invention also relates to a porous material obtainable by the method.

Abstract: The invention provides a method for preparing water dispersible or water soluble porous bodies and the bodies themselves The bodies have an intrusion volume as measured by mercury porosimetry of at least about 3 ml/g and comprise a three dimensional open-cell lattice containing less than 10% by weight of a water soluble polymeric material and 5 to 90% by weight of a surfactant, with the proviso that said porous bodies are not spherical beads having an average bead diameter of 0.2 to 5 mm.

Abstract: The present invention is directed to novel salts of thieno[2,3-d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The present invention is also directed to compositions including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.

Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.

Abstract: Porous bodies which are soluble or dispersible in non-aqueous media comprising a three dimensional open-cell lattice containing (a) 10 to 70% by weight of a polymeric material which is soluble in water immiscible non-aqueous media and (b) 30 to 90% by weight of a surfactant, said porous bodies having an intrusion volume as measured by mercury porosimetry of at least 3 ml/g.

Abstract: Disclosed is a compound of formula (I): crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including, e.g., cancer.

Abstract: This invention provides a compound of formula (I): or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; processes for the synthesis or manufacture of the compound of formula (I), or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; and the use of said compound, or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof, for the treatment of patients suffering from or subject to diseases, disorders or conditions involving cell survival, proliferation, and migration, including cardiovascular disease (e.g., arteriosclerosis and vascular reobstruction), cancer, (e.g., AML and malignant glioma)glomerulosclerosis, fibrotic disease and inflammation.

Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.

Abstract: A textile lapping machine has an inclined reciprocating comb which deposits a vertically descending fibrous web onto a mesh belt of an endless conveyor which travels through an oven. A reciprocating presser bar pushes the pleats formed by the comb into a shark unit which extends across the width of the mesh belt. The unit has a toothed plate which initially slows the pleated web and longitudinal fingers which overlie the conveyor and form a shallow lapping zone. A textile card delivers the fibrous web to the lapping zone and the oven fuses any low melt synthetic fibers in the web to the surrounding fibers to give a batt with a density of 80-2000 gsm. The comb path direction remains constant and the presser bar and shark unit are moved towards and away from the comb. The drives to the comb and presser bar are independent.

Abstract: Water dispersible or water soluble porous bodies comprising a three dimensional open-cell lattice containing 10 to 95% by weight of a polymeric material which is soluble in water, and, less than 5% by weight of a surfactant, said porous bodies having an intrusion volume as measured by mercury porosimetry (as hereinafter described) of at least about 3 ml/g, and, with the proviso that said porous bodies are not spherical beads having an average bead diameter of 0.2 to 5 mm.

Abstract: The present invention is directed to the compound of formula (II), or a solvate thereof, or crystalline forms thereof; to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (II), including crystalline forms thereof, and a pharmaceutically acceptable carrier; and to the use of a compound of formula (II), or crystalline forms thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting IKK-2, and methods related thereto.

Abstract: The present invention is directed to the Tartrate, Mono-Hydrochloride, Malonate and p-Toluenesulfonate Salts of the compound of formula (I), or solvates thereof, or crystalline forms thereof; to a pharmaceutical composition comprising a pharmaceutically effective amount of the Salts, including crystalline forms thereof, and a pharmaceutically acceptable carrier; and to the use of the Salts, including crystalline forms thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting IKK-2, and methods related thereto.

Abstract: The invention provides a method for the preparation of a carrier liquid which comprises the steps of: (I) preparing an emulsion comprising: a) an aqueous phase, b) A second liquid phase which is volatile and which is immiscible with aqueous phase (a), c) A carrier material which is soluble in the continuous phase of the emulsion and which is liquid at ambient temperature, and d) A dopant which is soluble in the disperse phase of the emulsion, (II) cooling the emulsion produced in step (I) to a temperature at which at least both the continuous phase and the carrier material become solid, (III) removing water and the volatile second phase from the cooled emulsion in vapor form, and, (IV) returning the product of step (III) to ambient temperature to obtain a liquid product with the dopant dispersed therein.

Abstract: Porous bodies which are soluble or dispersible in non-aqueous media comprising a three dimensional open-cell lattice containing (a) 10 to 70% by weight of a polymeric material which is soluble in water immiscible non-aqueous media and (b) 30 to 90% by weight of a surfactant, said porous bodies having an intrusion volume as measured by mercury porosimetry of at least 3 ml/g.

Abstract: The invention provides a method for preparing water dispersible or water soluble porous bodies and the bodies themselves The bodies have an intrusion volume as measured by mercury porosimetry of at least about 3 ml/g and comprise a three dimensional open-cell lattice containing less than 10% by weight of a water soluble polymeric material and 5 to 90% by weight of a surfactant, with the proviso that said porous bodies are not spherical beads having an average bead diameter of 0.2 to 5 mm.

Abstract: The invention provides a method comprising the steps of: (i) providing an emulsion of: a) an aqueous solvent, such as water, b) a carrier material dispersible or soluble in (a), said carrier material being solid at ambient temperature, and preferably being a polymer and inorganic salt or a surfactant, c) a volatile second liquid phase (for example, chloroform) which is not miscible with (a), and d) a material which is dispersible or soluble in (c) but not in (a), and, (ii) Drying the emulsion at above ambient temperature (preferably by spray drying) to simultaneously remove (a) and (c) and thereby obtain the material (b) in solid form with (d) dispersed therein.